Shots:

• The approval was based on the 5 trials i.e., JADE MONO-1/2, JADE COMPARE, dose-ranging trial & an ongoing OLE trial to evaluate the safety & efficacy of Cibinqo (100/200mg, qd) monothx vs PBO in 1600+ patients with AD whose disease is not adequately controlled with other systemic drugs
• The results showed improvements in skin clearance, severity & the extent of disease along with an improvement in itch @2wks. Additionally, a higher proportion of patients achieved an improvement in itching @12wks. & has a consistent safety profile
• Cibinqo is a JAK1 inhibitor & has received marketing authorization in the EU, Great Britain, Japan, Korea, the United Arab Emirates, Norway, Iceland, & Singapore

Ref: Pfizer | Image: The Wall Street Journal